Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.51 |
| ▸ | F2 | P00734 | 2/20 | 0.50 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.50 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.50 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | CA3 | P07451 | 1/20 | 0.45 |
| ▸ | CA6 | P23280 | 1/20 | 0.45 |
| ▸ | CA5A | P35218 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20187458 | 0.80 | ALDH1A1 (0.53) | GAALMNAALDH1A1SMN1; SMN2F2 | |
| SCHEMBL9738285 | 0.78 | F2 (0.53) | GAALMNAALDH1A1SMN1; SMN2F2 | |
| SCHEMBL135563 | 0.78 | F2 (0.53) | GAALMNAALDH1A1SMN1; SMN2F2 | |
| SCHEMBL5886057 | 0.77 | ALDH1A1 (0.53) | GAALMNAALDH1A1SMN1; SMN2F2 | |
| SCHEMBL16042071 | 0.75 | F2 (0.50) | GAALMNAALDH1A1SMN1; SMN2F2 | |
| SCHEMBL5138891 | 0.75 | F2 (0.59) | GAALMNAALDH1A1SMN1; SMN2F2 | |
| SCHEMBL9385131 | 0.73 | F2 (0.48) | GAALMNAALDH1A1SMN1; SMN2F2 | |
| SCHEMBL8789808 | 0.73 | ALDH1A1 (0.54) | GAALMNAALDH1A1SMN1; SMN2F2 | |
| SCHEMBL127246 | 0.73 | F2 (0.57) | GAALMNAALDH1A1SMN1; SMN2F2 | |
| SCHEMBL663730 | 0.73 | CYP2C19 (0.59) | GAALMNAALDH1A1SMN1; SMN2F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8003787-B2 | Sulphoximine-substituted quinoline and quinazoline derivatives as kinase inhibitors | BAYER SCHERING PHARMA AG (DE) | 2011-08-23 | — | — | US | disclosed |
| US-8003787-B2 | Sulphoximine-substituted quinoline and quinazoline derivatives as kinase inhibitors | BAYER SCHERING PHARMA AG (DE) | 2011-08-23 | — | — | US | disclosed |
| US-20090226377-A1 | NOVEL SULPHOXIMINE-SUBSTITUTED QUINOLINE AND QUINAZOLINE DERIVATIVES AS KINASE INHIBITORS | BAYER HEALTHCARE LLC (DE) | 2009-09-10 | — | — | US | disclosed |
| US-20090226377-A1 | NOVEL SULPHOXIMINE-SUBSTITUTED QUINOLINE AND QUINAZOLINE DERIVATIVES AS KINASE INHIBITORS | BAYER HEALTHCARE LLC (DE) | 2009-09-10 | — | — | US | disclosed |
| WO-2008141843-A1 | NOVEL SULPHOXIMINE-SUBSTITUTED QUINAZOLINE AND QUINAZOLINE DERIVATIVES AS KINASE INHIBITORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090226377-A1 | NOVEL SULPHOXIMINE-SUBSTITUTED QUINOLINE AND QUINAZOLINE DERIVATIVES AS KINASE INHIBITORS | MAP4K2, MAP3K20, MAP3K2 | GAA 1039/4885LMNA 3935/4885ALDH1A1 3510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.